GO
Loading...

Pharmaceuticals

More

  • Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • Shares of Array BioPharma soared Friday after the drug developer said it will buy worldwide rights to a potential cancer treatment in late-stage clinical testing from Swiss pharmaceutical giant Novartis. The Boulder, Colorado, company said the deal is conditional on Novartis closing some acquisitions with British drugmaker GlaxoSmithKline PLC that it...

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been dispatched to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The World Health Organization said on Thursday the Ebola outbreak in West Africa, the worst in history, appears to be waning but cautioned against complacency.

  • How health care is changing: Kaiser Permanente CEO Friday, 23 Jan 2015 | 7:13 AM ET
    Bernard Tyson at the 2015 WEF in Davos, Switzerland.

    Health care utilization is not dropping, but shifting toward a great focus on outpatient care, Bernard Tyson told CNBC.

  • Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The vaccine, co-developed by the National Institutes of Health in the United States and Okairos, a biotechnology firm acquired by GSK in 2013, is currently being tested...

  • Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.

  • US Sen. Warren to file bill targeting top drug companies Thursday, 22 Jan 2015 | 12:24 PM ET

    Elizabeth Warren is shifting her focus from Wall Street to the nation's top pharmaceutical companies. Warren's bill would require that whenever drug companies enter into a settlement with the government over alleged wrongdoing, they must pay a portion of their annual profits over five years to support research at the National Institutes of Health and the...

  • We are funding part of ACA: Novartis CEO  Thursday, 22 Jan 2015 | 8:14 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Joe Jimenez, Novartis CEO, discusses how the move in the Swiss franc impacted his company, innovative drugs in the pipeline, and pharmaceutical pricing issues.

  • DAVOS, Switzerland, Jan 21- Takeda Pharmaceutical, Japan's largest drugmaker, is ready to look at doing deals now that it has refocused operations, its incoming chief executive said on Wednesday. "We don't want to be passive and we don't want to watch the train passing," he told Reuters on the fringes of the World Economic Forum in Davos. As COO, Weber has overseen a...

  • Paying less than $16 per hour not fair: Aetna CEO Wednesday, 21 Jan 2015 | 9:41 AM ET
    Mark Bertolini, CEO of Aetna at 2015 WEF in Davos, Switzerland.

    Aetna raised employees' wages to a base of $16 per hour because doing otherwise would have put workers in poverty, CEO Mark Bertolini tells CNBC.

  • Jan 20- Johnson& Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck& Co.. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many...

  • Bristol-Myers names Caforio as CEO Tuesday, 20 Jan 2015 | 5:47 PM ET

    NEW YORK— Drugmaker Bristol-Myers Squibb said Tuesday that has named its chief operation officer, Giovanni Caforio, as its new CEO. Cornelius was CEO of Bristol-Myers Squibb Co. from 2006 to 2010. He became chairman in 2008, moving to non-executive chairman in May 2010. Shares of Bristol-Myers Squibb rose 14 cents to $62.45 Tuesday.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • Merck's 'not up for a big deal in 2015': Chair  Tuesday, 20 Jan 2015 | 11:30 AM ET

    Merck Chairman Karl-Ludwig Kley sheds some light on his company's plans for 2015, a year he forecasts will see less pharmaceutical M&A activity than 2014.

  • Davos: Who needs a 'wake up call'?  Tuesday, 20 Jan 2015 | 11:25 AM ET

    Discussing the current state of Europe at Davos 2015, Karl-Ludwig Kley, chairman of Merck says the lack of coordination and cohesion in European businesses is the current problem.Meanwhile political leaders need a wake-up call.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.